Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Petruccioli, Elisa ^a   Chiacchio, Teresa ^a   Vanini, Valentina ^a   Cuzzi, Gilda ^a   Codecasa, Luigi Ruffo ^b   Ferrarese, Maurizio ^b   Schininà, Vincenzo ^a   Palmieri, Fabrizio ^a   Ippolito, Giuseppe ^a   Goletti, Delia ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON;

ADULT; FEMALE; HUMAN; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TIME FACTOR; YOUNG ADULT;

ADULT; ANTIGENS, BACTERIAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; YOUNG ADULT;

EID: 85055603881     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-33825-w     Document Type: Article

References (37)

1. WHO. Global tuberculosis report 2017, www.who.int/tb/publications/global_report/en/ (2017)
2. Matteelli, A. et al. Numbers needed to treat to prevent tuberculosis. Eur. Respir. J. 46, 1838–1839 (2015)
3. Getahun, H. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J. 46, 1563–1576 (2015)
4. Lonnroth, K. et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur. Respir. J. 45, 928–952 (2015)
5. Goletti, D., Lee, M. R., Wang, J. Y., Walter, N. & Ottenhoff, T. H. M. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology 23, 455–466 (2018)
6. Goletti, D., Petruccioli, E., Joosten, S. A. & Ottenhoff, T. H. Tuberculosis Biomarkers: From Diagnosis to Protection. Infect. Dis. Rep. 8, 6568 (2016)
7. Denkinger, C. M. et al. Defining the needs for next generation assays for tuberculosis. J. Infect. Dis. 211(Suppl 2), S29–38 (2015)
8. Chiacchio, T. et al. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. PLoS One 12, e0183846 (2017)
9. Petruccioli, E. et al. Use of several immunological markers to model the probability of active tuberculosis. Diagn. Microbiol. Infect. Dis. 86, 169–171 (2016)
10. Petrone, L. et al. Blood and urine inducible protein 10 as potential markers of disease activity. Int. J. Tuberc. Lung Dis. 20, 1554–1561 (2016)
11. Petrone, L. et al. Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis inChildren. Biomed. Res. Int. 2015, 589471 (2015)
12. Petruccioli, E. et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J. Infect. 66, 475–486 (2013)
13. Petruccioli, E. et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur. Respir. J. 48, 1751–1763 (2016)
14. Whatney, W. E. et al. A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection. J. Immunol. 200, 3008–3019 (2018)
15. Igari, H. et al. Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis. J. Infect. Chemother. 24, 110–116 (2018)
16. Konig Walles, J. et al. Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS One 13, e0193589 (2018)
17. Rozot, V. et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin. Infect. Dis. 60, 432–437 (2015)
18. Musvosvi, M. et al. T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. Eur. Respir. J. 51, 10.1183/13993003.00153-2018. Print 2018 Mar (2018)
19. Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222–2232 (2011)
20. Day, C. L. et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS One 9, e94949 (2014)
21. Lewinsohn, D. A. et al. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am. J. Respir. Crit. Care Med. 168, 1346–1352 (2003)
22. Chiacchio, T. et al. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects. Immunol. Lett. 198, 33–43 (2018)
23. Chiacchio, T. et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J. Infect. 69, 533–545 (2014)
24. Lancioni, C. et al. CD8+ T cells provide an immunologic signature of tuberculosis in young children. Am. J. Respir. Crit. Care Med. 185, 206–212 (2012)
25. Rozot, V. et al. Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. 43, 1568–1577 (2013)
26. Barcellini, L. et al. First independent evaluation of QuantiFERON-TB Plus performance. Eur. Respir. J. 47, 1587–1590 (2016)
27. Barcellini, L. et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur. Respir. J. 48, 1411–1419 (2016)
28. Petruccioli, E. et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J. Infect. 73, 588–597 (2016)
29. Petruccioli, E. et al. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb) 106, 38–43 (2017)
30. QuantiFERON®-TB Gold Plus, ELISA Package Insert, QUIAGEN, http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf
31. Mazurek, G. H. et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 59, 1–25 (2010)
32. Nemes, E. et al. Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. Am. J. Respir. Crit. Care Med. 196, 638–648 (2017)
33. Metcalfe, J. Z. et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 187, 206–211 (2013)
34. Pai, M. et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int. J. Tuberc. Lung Dis. 13, 84–92 (2009)
35. Pieterman, E. D. et al. A multicentre verification study of the QuantiFERON((R))-TB Gold Plus assay. Tuberculosis (Edinb) 108, 136–142 (2018)
36. Kamada, A. & Amishima, M. QuantiFERON-TB((R)) Gold Plus as a potential tuberculosis treatment monitoring tool. Eur. Respir. J. 49, 10.1183/13993003.01976-2016. Print 2017 Mar (2017)
37. Moon, H. W. et al. Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting. J. Clin. Microbiol. 55, 1650–1657 (2017)